The estimated Net Worth of Bernard Ravina is at least $4.89 million dollars as of 4 January 2021. Dr Ravina owns over 45,000 units of Praxis Precision Medicines stock worth over $3,245,857 and over the last 7 years he sold PRAX stock worth over $848,673. In addition, he makes $799,813 as Chief Medical Officer at Praxis Precision Medicines.
Sign up
Dr Ravina PRAX stock SEC Form 4 insiders trading
Dr has made over 10 trades of the Praxis Precision Medicines stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 45,000 units of PRAX stock worth $102,150 on 4 January 2021.
The largest trade he's ever made was exercising 45,000 units of Praxis Precision Medicines stock on 4 January 2021 worth over $102,150. On average, Dr trades about 6,660 units every 84 days since 2017. As of 4 January 2021 he still owns at least 56,021 units of Praxis Precision Medicines stock.
You can see the complete history of Dr Ravina stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Bernard Ravina biography
Dr. Bernard Ravina is the Chief Medical Officer at Praxis Precision Medicines.
What is the salary of Dr Ravina?
As the Chief Medical Officer of Praxis Precision Medicines, the total compensation of Dr Ravina at Praxis Precision Medicines is $799,813. There are 1 executives at Praxis Precision Medicines getting paid more, with Marcio Souza M.B.A. having the highest compensation of $1,440,799.
How old is Dr Ravina?
Dr Ravina is 54, he's been the Chief Medical Officer of Praxis Precision Medicines since . There are no older and 4 younger executives at Praxis Precision Medicines.
What's Dr Ravina's mailing address?
Bernard's mailing address filed with the SEC is C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110.
Insiders trading at Praxis Precision Medicines
Over the last 4 years, insiders at Praxis Precision Medicines have traded over $16,246,895 worth of Praxis Precision Medicines stock and bought 242,294 units worth $603,092 . The most active insiders traders include Holdings A/S Novo, Parallel Master Fund L.P.Bl... et Dean J Mitchell. On average, Praxis Precision Medicines executives and independent directors trade stock every 48 days with the average trade being worth of $3,178,530. The most recent stock trade was executed by Jill De Simone on 5 October 2023, trading 14,500 units of PRAX stock currently worth $25,375.
What does Praxis Precision Medicines do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
What does Praxis Precision Medicines's logo look like?
Complete history of Dr Ravina stock trades at Voyager Therapeutics Inc et Praxis Precision Medicines
Praxis Precision Medicines executives and stock owners
Praxis Precision Medicines executives and other stock owners filed with the SEC include:
-
Marcio Souza M.B.A.,
Pres, CEO & Director -
Dr. Bernard Ravina,
Chief Medical Officer -
Nicole Sweeny,
Chief Commercial Officer -
Alex Kane,
VP of Investor Relations & Corp. Communications -
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.,
Co-Founder & Chief Scientific Officer -
Karl Hansen,
Sr. VP of CMC -
Kelly McCue,
Chief People Officer -
Alex Nemiroff J.D.,
Gen. Counsel & Sec. -
Lauren Mastrocola,
VP of Fin. & Principal Accounting Officer -
Timothy Edwin Kelly,
CFO & Treasurer -
Dr. Steven Petrou,
Co-Founder & Chief Scientific Officer -
Dr. David B. Goldstein Ph.D.,
Co-Founder -
Stefan Vitorovic,
Director -
Jeffrey Chodakewitz,
Director -
Lifesciences Iii, L.P.Claru...,
-
Gregory Norden,
Director -
William D Young,
Director -
Dean J Mitchell,
Director -
Parallel Master Fund L.P.Bl...,
-
Jill De Simone,
Director -
Alex Nemiroff,
General Counsel and Secretary -
Nicole Sweeny,
Chief Commercial Officer -
Holdings A/S Novo,
10% owner -
Bernard Ravina,
Chief Medical Officer -
Merit Ester Cudkowicz,
Director -
Lifesciences Iii, L.P.Claru...,
-
Timothy Edwin Kelly,
Chief Financial Officer -
Parallel Master Fund L.P.Bl...,
-
Marcio Souza,
Chief Executive Officer